Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey ...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

As we observe Endometriosis Awareness Month in March, let us take a look at 7 biotech companies advancing promising ...

A receding hairline may be common — about two-thirds of men start losing their hair by age 35 — but that doesn’t make it any ...

The erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected to reach $ 14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028. Rise in number of patients ...

Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company that specializes in diabetes care and other chronic ...

Endometrial organoids, 3D cell cultures mimicking the endometrium, offer new opportunities in endometriosis research. These ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...